BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 31, 2011
 |  BioCentury  |  Strategy

Selectin selection

GlycoMimetics licensed sickle cell agent to Pfizer to grow rest of pipeline

When GlycoMimetics Inc.'s GMI-1070 sickle cell disease therapeutic received much less money from the government's therapeutic tax credit awards than the company had requested, the biotech had to use more of its own dollars on the project and thus had less to spend on other research. Now that it has partnered the selectin-based compound with Pfizer Inc., GlycoMimetics expects it has freed up enough resources to get back into the clinic with a cancer candidate in 12-18 months.

GlycoMimetics was founded based on CSO John Magnani's research on the biology of carbohydrates, in particular a family of cell adhesion molecules called selectins.

The first program to emerge was GMI-1070, a synthetic glycomimetic molecule. In 2007, GlycoMimetics published in The Proceedings of the National Academy of Sciences that GMI-1070 restored blood flow to normal levels and eliminated the adhesion of sickle red blood cells and leukocytes in...

Read the full 724 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >